Figures & data
Table I. Trends in survival for prostate cancer by country. Number of tumours (N) included and the 5- and 10-year age-standardised (ICSS) relative survival in percent with 95% confidence intervals (RS (CI)). Nordic cancer survival study 1964–2003.
Figure 1. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5- and 10-year relative survival for prostate cancer by country. Nordic cancer survival study 1964–2003.
![Figure 1. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5- and 10-year relative survival for prostate cancer by country. Nordic cancer survival study 1964–2003.](/cms/asset/2fd501b9-9677-40f6-9ae8-212312829f3d/ionc_a_458027_f0001_b.jpg)
Table II. Trends in 5- and 10-year age-specific relative survival in percent after prostate cancer by country. Nordic cancer survival study 1964–2003.
Figure 2. Trends in age-standardised (ICSS) excess death rates per 100 person years for prostate cancer by country and time since diagnosis in Nordic cancer survival study 1964–2003.
![Figure 2. Trends in age-standardised (ICSS) excess death rates per 100 person years for prostate cancer by country and time since diagnosis in Nordic cancer survival study 1964–2003.](/cms/asset/274fab35-3f9d-4ade-9a01-a8483ef43c36/ionc_a_458027_f0002_b.jpg)
Figure 3. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5-year relative survival for testis cancer by country. Nordic cancer survival study 1964–2003.
![Figure 3. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5-year relative survival for testis cancer by country. Nordic cancer survival study 1964–2003.](/cms/asset/f2936fac-7c52-4b3f-8c8c-e770c2988989/ionc_a_458027_f0003_b.jpg)
Table III. Trends in survival for testis cancer by country. Number of tumours (N) included and the 5-year age-standardised (ICSS) relative survival in percent with 95% confidence intervals (RS (CI)). Nordic cancer survival study 1964–2003.
Figure 4. Trends in age-standardised (ICSS) excess death rates per 100 person years for testis cancer by country and time since diagnosis in Nordic cancer survival study 1964–2003. No Icelandic curves. Too few partients to calculate survival in Iceland.
![Figure 4. Trends in age-standardised (ICSS) excess death rates per 100 person years for testis cancer by country and time since diagnosis in Nordic cancer survival study 1964–2003. No Icelandic curves. Too few partients to calculate survival in Iceland.](/cms/asset/af0c8458-68d0-40da-89ec-7a93db04c48f/ionc_a_458027_f0004_b.jpg)
Table IV. Trends in 5-year age-specific relative survival in percent after testis cancer by country. Nordic cancer survival study 1964–2003.
Figure 5. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5-year relative survival for cancer of the penis and other male genital organs by country. Nordic cancer survival study 1964–2003.
![Figure 5. Trends in age-standardised (World) incidence and mortality rates per 100 000 and age-standardised (ICSS) 5-year relative survival for cancer of the penis and other male genital organs by country. Nordic cancer survival study 1964–2003.](/cms/asset/1061d790-850f-4734-8859-e7e50fcaae9f/ionc_a_458027_f0005_b.jpg)
Table V. Trends in survival for cancer of the penis and other male genital organs by country. Number of tumours (N) included and the 5-year age-standardised (ICSS) relative survival in percent with 95% confidence intervals (RS (CI)). Nordic cancer survival study 1964–2003.
Figure 6. Trends in age-standardised (ICSS) excess death rates per 100 person years for cancer of the penis and other male genital organs by country and time since diagnosis in Nordic cancer survival study 1964–2003. No Icelandic curves. Too few partients to calculate survival for Iceland.
![Figure 6. Trends in age-standardised (ICSS) excess death rates per 100 person years for cancer of the penis and other male genital organs by country and time since diagnosis in Nordic cancer survival study 1964–2003. No Icelandic curves. Too few partients to calculate survival for Iceland.](/cms/asset/c64f51de-82e6-41f2-8bb8-d1b8944f817f/ionc_a_458027_f0006_b.jpg)
Table VI. Trends in 5-year age-specific relative survival in percent after cancer of the penis and other male genital organs by country. Nordic cancer survival study 1964–2003.